These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17622941)

  • 1. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.
    Ho RH; Choi L; Lee W; Mayo G; Schwarz UI; Tirona RG; Bailey DG; Stein CM; Kim RB
    Pharmacogenet Genomics; 2007 Aug; 17(8):647-56. PubMed ID: 17622941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
    Kivistö KT; Niemi M
    Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
    Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
    Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
    Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
    Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
    Aquilante CL; Kiser JJ; Anderson PL; Christians U; Kosmiski LA; Daily EB; Hoffman KL; Hopley CW; Predhomme JA; Schniedewind B; Sidhom MS
    J Clin Pharmacol; 2012 Nov; 52(11):1725-38. PubMed ID: 22174437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
    Niemi M; Schaeffeler E; Lang T; Fromm MF; Neuvonen M; Kyrklund C; Backman JT; Kerb R; Schwab M; Neuvonen PJ; Eichelbaum M; Kivistö KT
    Pharmacogenetics; 2004 Jul; 14(7):429-40. PubMed ID: 15226675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
    Deng JW; Song IS; Shin HJ; Yeo CW; Cho DY; Shon JH; Shin JG
    Pharmacogenet Genomics; 2008 May; 18(5):424-33. PubMed ID: 18408565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.
    Zhang W; He YJ; Gan Z; Fan L; Li Q; Wang A; Liu ZQ; Deng S; Huang YF; Xu LY; Zhou HH
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1240-4. PubMed ID: 17973861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
    Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
    Igel M; Arnold KA; Niemi M; Hofmann U; Schwab M; Lütjohann D; von Bergmann K; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2006 May; 79(5):419-26. PubMed ID: 16678544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
    Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
    Li R; Barton HA
    Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
    Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Rattanacheeworn P; Chamnanphon M; Thongthip S; Kittanamongkolchai W; Townamchai N; Avihingsanon Y; Udomnilobol U; Prueksaritanont T; Jianmongkol S; Chariyavilaskul P
    Pharmgenomics Pers Med; 2020; 13():521-530. PubMed ID: 33122935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
    Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLCO1B1 polymorphism and oral antidiabetic drugs.
    Kalliokoski A; Neuvonen PJ; Niemi M
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.
    Mwinyi J; Johne A; Bauer S; Roots I; Gerloff T
    Clin Pharmacol Ther; 2004 May; 75(5):415-21. PubMed ID: 15116054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.